Grifols, S.a. (GRFS)

$6.56

-0.09

(-1.35%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Grifols, S.a.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 1.71B → 1.59B (in $), with an average decrease of 3.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 60.03M → 59.54M (in $), with an average decrease of 0.8% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 100.6% return, outperforming this stock by 113.5%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 310.7% return, outperforming this stock by 374.0%

Performance

  • $6.49
    $6.63
    $6.56
    downward going graph

    1.07%

    Downside

    Day's Volatility :2.11%

    Upside

    1.06%

    downward going graph
  • $5.30
    $12.15
    $6.56
    downward going graph

    19.21%

    Downside

    52 Weeks Volatility :56.38%

    Upside

    46.01%

    downward going graph

Returns

PeriodGrifols, S.a.Sector (Health Care)Index (Russel 2000)
3 Months
-10.5%
-1.1%
0.0%
6 Months
-24.94%
6.7%
0.0%
1 Year
-12.88%
3.2%
-0.7%
3 Years
-63.27%
17.2%
-21.3%

Highlights

Market Capitalization
5.4B
Book Value
$8.58
Earnings Per Share (EPS)
0.1
PE Ratio
66.35
PEG Ratio
0.28
Wall Street Target Price
15.86
Profit Margin
0.9%
Operating Margin TTM
12.78%
Return On Assets TTM
2.14%
Return On Equity TTM
2.2%
Revenue TTM
6.6B
Revenue Per Share TTM
4.85
Quarterly Revenue Growth YOY
3.3000000000000003%
Gross Profit TTM
2.2B
EBITDA
1.0B
Diluted Eps TTM
0.1
Quarterly Earnings Growth YOY
1.79
EPS Estimate Current Year
0.87
EPS Estimate Next Year
1.19
EPS Estimate Current Quarter
0.24
EPS Estimate Next Quarter
0.34

Analyst Recommendation

Buy
    68%Buy
    28%Hold
    4%Sell
Based on 25 Wall street analysts offering stock ratings for Grifols, S.a.(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
17
Hold
7
7
7
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 141.77%

Current $6.56
Target $15.86

Company Financials

FY18Y/Y Change
Revenue
4.5B
↑ 3.91%
Net Income
596.6M
↓ 9.97%
Net Profit Margin
13.3%
↓ 2.05%
FY19Y/Y Change
Revenue
5.1B
↑ 13.64%
Net Income
625.1M
↑ 4.78%
Net Profit Margin
12.26%
↓ 1.04%
FY20Y/Y Change
Revenue
5.3B
↑ 4.73%
Net Income
618.5M
↓ 1.06%
Net Profit Margin
11.58%
↓ 0.68%
FY21Y/Y Change
Revenue
5.6B
↓ 7.62%
Net Income
300.5M
↓ 57.1%
Net Profit Margin
5.38%
↓ 6.2%
FY22Y/Y Change
Revenue
6.5B
↑ 22.92%
Net Income
223.1M
↓ 21.5%
Net Profit Margin
3.43%
↓ 1.95%
FY23Y/Y Change
Revenue
6.6B
↑ 8.71%
Net Income
59.3M
↓ 71.52%
Net Profit Margin
0.9%
↓ 2.53%
Q2 FY22Q/Q Change
Revenue
1.6B
↑ 67.98%
Net Income
94.4M
↓ 148.38%
Net Profit Margin
5.86%
↑ 26.19%
Q3 FY22Q/Q Change
Revenue
1.5B
↓ 0.11%
Net Income
43.8M
↓ 50.68%
Net Profit Margin
2.89%
↓ 2.97%
Q4 FY22Q/Q Change
Revenue
1.8B
↑ 11.14%
Net Income
21.5M
↓ 54.96%
Net Profit Margin
1.17%
↓ 1.72%
Q1 FY23Q/Q Change
Revenue
1.9B
↑ 0.0%
Net Income
21.9M
↑ 0.0%
Net Profit Margin
1.17%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
1.8B
↓ 2.88%
Net Income
65.5M
↑ 199.13%
Net Profit Margin
3.61%
↑ 2.44%
Q3 FY23Q/Q Change
Revenue
1.6B
↓ 3.97%
Net Income
59.5M
↓ 0.82%
Net Profit Margin
3.73%
↑ 0.12%
FY18Y/Y Change
Total Assets
12.5B
↑ 14.26%
Total Liabilities
7.8B
↑ 6.78%
FY19Y/Y Change
Total Assets
15.5B
↑ 24.57%
Total Liabilities
8.7B
↑ 11.78%
FY20Y/Y Change
Total Assets
15.3B
↓ 1.72%
Total Liabilities
8.6B
↓ 1.63%
FY21Y/Y Change
Total Assets
21.8B
↑ 25.92%
Total Liabilities
12.6B
↑ 29.6%
FY22Y/Y Change
Total Assets
23.1B
↑ 11.96%
Total Liabilities
14.0B
↑ 17.95%
FY23Y/Y Change
Total Assets
21.5B
↓ 0.37%
Total Liabilities
13.5B
↑ 3.0%
Q2 FY22Q/Q Change
Total Assets
22.0B
↑ 29.77%
Total Liabilities
13.2B
-
Q3 FY22Q/Q Change
Total Assets
21.2B
↑ 2.35%
Total Liabilities
12.9B
↑ 3.62%
Q4 FY22Q/Q Change
Total Assets
22.9B
↓ 0.85%
Total Liabilities
14.1B
↑ 0.76%
Q1 FY23Q/Q Change
Total Assets
21.5B
↑ 0.86%
Total Liabilities
13.1B
↓ 0.75%
Q2 FY23Q/Q Change
Total Assets
23.4B
↓ 0.47%
Total Liabilities
14.4B
↑ 1.02%
Q3 FY23Q/Q Change
Total Assets
22.1B
↑ 2.95%
Total Liabilities
13.5B
↑ 2.17%
FY18Y/Y Change
Operating Cash Flow
737.4M
↓ 12.39%
Investing Cash Flow
-781.9M
↓ 64.23%
Financing Cash Flow
152.5M
↓ 89.37%
FY19Y/Y Change
Operating Cash Flow
568.9M
↓ 22.85%
Investing Cash Flow
-548.8M
↓ 29.81%
Financing Cash Flow
-332.4M
↓ 317.93%
FY20Y/Y Change
Operating Cash Flow
1.1B
↑ 95.16%
Investing Cash Flow
-858.1M
↑ 56.37%
Financing Cash Flow
-354.4M
↑ 6.63%
FY21Y/Y Change
Operating Cash Flow
676.1M
↓ 46.23%
Investing Cash Flow
-33.3M
↓ 96.57%
Financing Cash Flow
1.7B
↓ 515.61%
FY22Y/Y Change
Operating Cash Flow
-11.6M
↓ 101.82%
Investing Cash Flow
-2.1B
↑ 6632.29%
Financing Cash Flow
-185.9M
↓ 111.78%
Q2 FY22Q/Q Change
Operating Cash Flow
-3.6M
↓ 121.72%
Investing Cash Flow
-938.7M
↑ 0.0%
Financing Cash Flow
-460.6M
↑ 103.8%
Q3 FY22Q/Q Change
Operating Cash Flow
-108.0M
↑ 3109.08%
Investing Cash Flow
-37.1M
↓ 95.8%
Financing Cash Flow
56.0M
↓ 112.92%
Q4 FY22Q/Q Change
Operating Cash Flow
-22.7M
↓ 80.71%
Investing Cash Flow
-97.4M
↑ 140.69%
Financing Cash Flow
138.8M
↑ 127.46%
Q1 FY23Q/Q Change
Operating Cash Flow
-23.1M
↑ 0.0%
Investing Cash Flow
-134.0M
↑ 35.21%
Financing Cash Flow
141.3M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-46.1M
↑ 99.41%
Investing Cash Flow
-134.1M
↑ 0.0%
Financing Cash Flow
207.2M
↑ 46.56%
Q3 FY23Q/Q Change
Operating Cash Flow
155.6M
↓ 468.16%
Investing Cash Flow
-122.9M
↑ 0.0%
Financing Cash Flow
-79.4M
↓ 141.79%

Technicals Summary

Sell

Neutral

Buy

Grifols, S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Grifols, S.a.
Grifols, S.a.
13.89%
-24.94%
-12.88%
-63.27%
-66.32%
Eli Lilly And Company
Eli Lilly And Company
-1.19%
21.89%
100.58%
310.73%
505.77%
Johnson & Johnson
Johnson & Johnson
-7.34%
-6.35%
-11.05%
-7.75%
8.06%
Merck & Co. Inc.
Merck & Co. Inc.
4.34%
20.74%
9.05%
64.58%
60.12%
Abbvie Inc
Abbvie Inc
-10.44%
10.22%
0.43%
53.24%
100.27%
Pfizer Inc.
Pfizer Inc.
-8.07%
-22.27%
-37.22%
-30.43%
-38.56%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Grifols, S.a.
Grifols, S.a.
66.35
66.35
0.28
0.87
0.02
0.02
NA
8.58
Eli Lilly And Company
Eli Lilly And Company
131.6
131.6
1.45
12.49
0.48
0.12
0.01
11.98
Johnson & Johnson
Johnson & Johnson
28.88
28.88
0.9
10.65
0.18
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
905.36
905.36
0.1
8.57
0.01
0.03
0.02
14.85
Abbvie Inc
Abbvie Inc
61.65
61.65
0.46
11.21
0.35
0.08
0.03
5.87
Pfizer Inc.
Pfizer Inc.
70.97
70.97
0.26
2.2
0.02
0.02
0.06
15.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Grifols, S.a.
Grifols, S.a.
Buy
$5.4B
-66.32%
66.35
0.9%
Eli Lilly And Company
Eli Lilly And Company
Buy
$724.5B
505.77%
131.6
15.36%
Johnson & Johnson
Johnson & Johnson
Hold
$361.9B
8.06%
28.88
41.28%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$321.0B
60.12%
905.36
0.61%
Abbvie Inc
Abbvie Inc
Buy
$296.9B
100.27%
61.65
8.95%
Pfizer Inc.
Pfizer Inc.
Buy
$148.7B
-38.56%
70.97
3.62%

Institutional Holdings

  • Capital World Investors

    2.91%
  • Millennium Management LLC

    2.32%
  • Brandes Investment Partners & Co

    1.99%
  • Black Creek Investment Management Inc

    1.36%
  • Flat Footed LLC

    1.08%
  • Pictet Asset Manangement SA

    1.06%

Corporate Announcements

  • Grifols, S.a. Dividends September,2021

    In the quarter ending September,2021. Grifols, S.a. has declared dividend of $0.46

    Read More

Company Information

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t

Organization
Grifols, S.a.
Employees
23744
CEO
Mr. Thomas H. Glanzmann
Industry
Health Technology

FAQs